6622.HK

Zhaoke Ophthalmology's Partner Vyluma Announces Positive Results from Phase III CHAMP Study of NVK002 for Treatment of Myopia Progression in Children

Retrieved on: 
Friday, October 28, 2022

Analysis of this multi-center, international study, performed after three years of treatment and follow up, demonstrates strong safety and efficacy for NVK002 as a potential treatment for the progression of myopia in children.

Key Points: 
  • Analysis of this multi-center, international study, performed after three years of treatment and follow up, demonstrates strong safety and efficacy for NVK002 as a potential treatment for the progression of myopia in children.
  • CHAMP is a three-arm, randomized, double-masked, placebo-controlled Phase III clinical study conducted across the U.S. and Europe in nearly 600 children and adolescents aged three to seventeen years at enrollment.
  • "The CHAMP study shows us that Vyluma's novel formulation of low-dose atropine can make a clinically meaningful difference in treating children with myopia.
  • If approved by the FDA, NVK002 would be a first-in-class, clinically proven pharmaceutical agent for the treatment of myopia progression in children.

Zhaoke Ophthalmology Announces 2022 Interim Results

Retrieved on: 
Wednesday, August 24, 2022

Dr. Li Xiaoyi (Benjamin), Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology, said, "Innovation and commercialization are Zhaoke Ophthalmology's dual focuses for 2022.

Key Points: 
  • Dr. Li Xiaoyi (Benjamin), Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology, said, "Innovation and commercialization are Zhaoke Ophthalmology's dual focuses for 2022.
  • In May 2022, Zhaoke Ophthalmology announced a new partnership with Visus, a US pharmaceutical company, to license BRIMOCHOL(TM) PF and Carbachol PF, innovative drugs for presbyopia.
  • Dr. Li continued, "Looking forward, we anticipate the second half of 2022 will be an exciting period for Zhaoke Ophthalmology.
  • Phase III pivotal trials commenced in March 2022, with interim topline data expected in the fourth quarter of 2022.